PTGS2 and prostate carcinoma: Celecoxib is a selective COX-2 inhibitor, and it is known that Cx exhibits anticancer effects in models in vitro and in vivo, including colon, lung, and prostate cancer; however, its anticancer activity involves COX-dependent and -independent mechanisms [13].